Significados de proteasome inhibitor en inglés

The proteasome inhibitor bortezomib is an efficacious apoptotic agent in many tumor cells.

Bortezomib is the first proteasome inhibitor drug tested in human patients.

However, a significant proportion of patients who receive a proteasome inhibitor-containing regime show cardiotoxicity.

Therefore, the proteasome inhibitor MG132 should be further evaluated for combination therapy with TRAIL.

The introduction of proteasome inhibitor and immunomodulatory drugs has considerably changed the treatment paradigm of multiple myeloma.

These results demonstrate the involvement of PRDM1beta in T-cell lymphoma, with possible therapeutic interference by the proteasome inhibitor.

In the present study, we studied the effect of the proteasome inhibitor MLN-273 in two HBV mouse models.

Finally, treatment of tumor cells with Ad-mda7 plus the proteasome inhibitor bortezomib resulted in increased tumor cell killing.

Strikingly, inclusion of the proteasome inhibitor bortezomib reduces thrombotic risk, yet the molecular basis for this observation remains unknown.

Rapid development of the small molecule proteasome inhibitor bortezomib has yielded important clinical benefit for patients with multiple myeloma.

The proteasome inhibitor bortezomib is approved by the US Food and Drug Administration for treatment of mantle cell lymphoma.

Application of the proteasome inhibitor MG132 restored the ability of the Xcv ΔxopJ to attenuate the development of leaf necrosis.

We first generated a yeast strain with an epitope tagged proteasome subunit to which a proteasome inhibitor could be applied.

The impact of in vitro exposure to the proteasome inhibitor bortezomib was next evaluated in primary mantle cell lymphoma cells.

These studies explain a fundamental mechanism by which cells adapt to proteotoxic stress and suggest strategies to mitigate proteasome inhibitor resistance.

We found that the reduction in tyrosinase levels that was induced by terrein was clearly recovered by MG-132, a proteasome inhibitor.